<?xml version="1.0" encoding="UTF-8"?><REUTERS CGISPLIT="TRAINING-SET" LEWISSPLIT="TEST" NEWID="17520" OLDID="5858" TOPICS="NO">
<DATE> 1-JUN-1987 09:46:27.25</DATE>
<TOPICS/>
<PLACES><D>usa</D></PLACES>
<PEOPLE/>
<ORGS/>
<EXCHANGES/>
<COMPANIES/>
<UNKNOWN> 
   F
   f0978 reute
r f BC-SCHERING-PLOUGH-&lt;SGP&gt;   06-01 0074</UNKNOWN>
<TEXT> 
<TITLE>SCHERING-PLOUGH &lt;SGP&gt; GETS FDA APPROVAL</TITLE>
<DATELINE>    MADISON, N.J., June 1 - </DATELINE><BODY>Schering-Plough Corp said its
Elocon topical steroid for inflammatory skin disorders has been
approved for marketing by the U.S. Food and Drug Administration
in cream and ointment forms for once-daily applications.
    The company said overseas health agency registrations for
Elocon are scheduled to be submitted in a number of major
markets this year and in other areas in 1988.
 Reuter
 </BODY></TEXT>
</REUTERS>